The European Medicines Agency (EMA) announced on Thursday March 4 that it had started examining the Russian vaccine Sputnik V, a crucial step in view of its deployment in the European Union.
Read also: Covid-19: Sputnik V, a very political Russian vaccine
"
The AEM has started an ongoing study of Sputnik V, a vaccine against Covid-19 developed by the Russian national center Gamaleya for epidemiology and microbiology,
" the Amsterdam-based agency said in a statement.
Following this announcement, the Russian authorities said they were ready to provide vaccines to 50 million Europeans from June. "
Following the approval of the EMA, we would be able to provide vaccines for 50 million Europeans from June 2021,
" Kirill Dmitriev, head of the Russian sovereign wealth fund, who contributed to the fund, said in a statement in a statement. development of this vaccine.